Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Further information on Pharmacokinetic Properties
Absorption and Distribution
The half-life of Forsteo is approximately 1 hour when administered subcutaneously, which reflects the time required for absorption from the injection site. 1
Teriparatide is rapidly and extensively absorbed following subcutaneous injection, with a maximum serum concentration at approximately 30 minutes.2,3
The volume of distribution is approximately 1.7 L/kg.1
Biotransformation and Elimination
No metabolism or excretion studies have been performed with Forsteo but the peripheral metabolism of parathyroid hormone is believed to occur predominantly in liver and kidney.1
Forsteo is eliminated through hepatic and extra-hepatic clearance (approximately 62 L/hr in women and 94 L/hr in men).1
Teriparatide is rapidly eliminated with a decrease to nonquantifiable concentrations within 3 hours of the dose.3
1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Satterwhite J, Heathman M, Miller PD, et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010;87(6):485-492. http://dx.doi.org/10.1007/s00223-010-9424-6
3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Datum fӧr senaste ӧversyn 2019 M11 11